Patents by Inventor Danja Grossbach
Danja Grossbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220257547Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.Type: ApplicationFiled: April 29, 2022Publication date: August 18, 2022Applicants: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
-
Patent number: 11344519Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.Type: GrantFiled: December 23, 2020Date of Patent: May 31, 2022Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFTInventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
-
Publication number: 20210113504Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.Type: ApplicationFiled: December 23, 2020Publication date: April 22, 2021Applicants: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
-
Patent number: 10905667Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.Type: GrantFiled: July 24, 2018Date of Patent: February 2, 2021Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFTInventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
-
Publication number: 20200237648Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal, pulmonary and ophthalmic disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.Type: ApplicationFiled: July 19, 2019Publication date: July 30, 2020Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFTInventors: ANKE STROYER, Carmen LOBBACK, Peter SERNO, Kia LOVIS, Philipp RUBENBAUER, Helko SCHIRMER, Danja GROßBACH, Tia JACOBS, Britta OLENIK, Julia Küsel, Donald BIERER
-
Publication number: 20200030270Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.Type: ApplicationFiled: July 24, 2018Publication date: January 30, 2020Applicants: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Kusel
-
Patent number: 10494372Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.Type: GrantFiled: November 5, 2015Date of Patent: December 3, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Jan-Georg Peters, Philipp Rubenbauer, Daniel Götz, Danja Großbach, Franz-Josef Mais, Heiko Schirmer, Juergen Stiehl, Kai Lovis, Andreas Lender, Martin Seyfried, Theodor Zweifel, Maurus Marty, Günter Weingärtner
-
Publication number: 20180282337Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.Type: ApplicationFiled: November 5, 2015Publication date: October 4, 2018Applicants: Bayer Pharma Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Jan-Georg PETERS, Philipp RUBENBAUER, Daniel GÖTZ, Danja GROßBACH, Franz-Josef MAIS, Heiko SCHIRMER, Juergen STIEHL, Kai LOVIS, Andreas LENDER, Martin SEYFRIED, Theodor ZWEIFEL, Maurus MARTY, Günter WEINGÄRTNER
-
Publication number: 20130116443Abstract: The present invention relates to a process for the preparation of substituted 3-(2-hydroxyethyl)-1-[4-nitrophenyl]pyridin-2(1H)-ones which serve as important intermediate compounds for producing drugs.Type: ApplicationFiled: April 26, 2011Publication date: May 9, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Joachim Krüger, Danja Grossbach, Holger Paulsen, Walter Kroh
-
Patent number: 8049035Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.Type: GrantFiled: February 7, 2011Date of Patent: November 1, 2011Assignee: Bayer Pharma AGInventors: Tilo Haag, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
-
Patent number: 7994346Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.Type: GrantFiled: November 3, 2006Date of Patent: August 9, 2011Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Danja Grossbach, William Guilford, Michael Sander
-
Publication number: 20110124910Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.Type: ApplicationFiled: February 7, 2011Publication date: May 26, 2011Inventors: Tilo HAAG, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
-
Patent number: 7906678Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.Type: GrantFiled: December 3, 2007Date of Patent: March 15, 2011Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Tilo Haag, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
-
Patent number: 7763743Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.Type: GrantFiled: November 3, 2006Date of Patent: July 27, 2010Assignee: Bayer Schering Pharma AGInventors: Danja Grossbach, William Guilford, Michael Sander
-
Publication number: 20090062558Abstract: The present invention relates to a new process for preparing estrogen-antagonistic 11?-fluoro-17?-alkylestra-1,3,5(10)-triene-3,17-diols of the general formula I having a 7?-(?-alkylamino-?-perfluoroalkyl)alkyl side chain and to ?-alkyl(amino)-?-perfluoro(alkyl)alkanes of the general formula II, to processes for their preparation and to the intermediates required for this purpose.Type: ApplicationFiled: August 29, 2008Publication date: March 5, 2009Inventors: Michael SANDER, Danja Grossbach, Christian Dinter, Jorma Hassfeld, David Voigtlaender
-
Publication number: 20090036530Abstract: This invention is directed to a crystalline acid of a lipoxin A4 analog of Formula (II): wherein: R1 is —O—, —S(O)t— (where t is 0, 1 or 2), or a straight or branched alkylene chain; and R2 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from f alkyl, alkoxy, halo, haloalkyl and haloalkoxy); and wherein the compound of Formula (II) is a single stereoisomer or any mixture of stereoisomers. This crystalline acid is useful in treating disease-states characterized by inflammation, such as inflammatory and autoimmune disorders or pulmonary or respiratory tract inflammations in humans. Methods of preparing the crystalline acid are also described.Type: ApplicationFiled: June 30, 2008Publication date: February 5, 2009Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Klaus Bartel, Danja Grossbach, William J. Guilford, Michael Sander, Gabriele Winter
-
Publication number: 20080182897Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.Type: ApplicationFiled: December 3, 2007Publication date: July 31, 2008Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Tilo Haag, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
-
Publication number: 20080182901Abstract: This invention is directed to a crystalline acid of a lipoxin A4 analog of Formula (II): wherein: R1 is —O—, —S(O)t— (where t is 0, 1 or 2), or a straight or branched alkylene chain; and R2 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from f alkyl, alkoxy, halo, haloalkyl and haloalkoxy); and wherein the compound of Formula (II) is a single stereoisomer or any mixture of stereoisomers. This crystalline acid is useful in treating disease-states characterized by inflammation, such as inflammatory and autoimmune disorders or pulmonary or respiratory tract inflammations in humans. Methods of preparing the crystalline acid are also described.Type: ApplicationFiled: December 3, 2007Publication date: July 31, 2008Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Klaus Bartel, Danja Grossbach, William J. Guilford, Michael Sander, Gabriele Winter
-
Publication number: 20070105949Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.Type: ApplicationFiled: November 3, 2006Publication date: May 10, 2007Applicant: Schering AktiengesellschaftInventors: Danja Grossbach, William Guilford, Michael Sander
-
Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs
Publication number: 20060167025Abstract: The invention relates to tricyclic amino alcohols of general formula (I) method for synthesis of same and use of same as anti-inflammatory agents.Type: ApplicationFiled: December 21, 2005Publication date: July 27, 2006Inventors: Markus Berger, Norbert Schmees, Heike Schaecke, Stefan Baurle, Hartmut Rehwinkel, Anne Mengel, Konrad Krolikiewicz, Danja Grossbach, David Voigtlaender